Ricardo E Blanco - Epidemiology

Author Information

Ricardo Blanco is a prominent researcher affiliated with the Division of Rheumatology and the Epidemiology, Genetics, and Atherosclerosis Research Group on Systemic Inflammatory Diseases at Hospital Universitario Marqués de Valdecilla, IDIVAL, in Santander, Spain. His expertise in rheumatology, particularly in systemic inflammatory diseases, has significantly contributed to the field.

Research Contributions

Ricardo Blanco has made substantial contributions to the understanding and treatment of various autoimmune and inflammatory diseases. His recent work includes studies on the cardioprotective effects of antimalarials in lupus patients, advances in treating giant cell arteritis, and the utility of tocilizumab in autoimmune eye diseases. Blanco has also delved into biologic therapy for refractory Neurobehçet's disease and the potential of angiogenic T cells as biomarkers for early diagnosis of interstitial lung disease in autoimmune diseases. His research is characterized by a focus on improving diagnostic and therapeutic approaches for complex rheumatologic conditions.

Aliases

R Blanco, R. Blanco, Ricardo Blanco, Ricardo E Blanco

Publication and Citation Metrics

Metric	Value
Citation Count	12,253
h-index	58
Paper Count	635

Publications:

Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

DOI: 10.1016/j.semarthrit.2021.11.012

Year: 2022

Advances in the Treatment of Giant Cell Arteritis

DOI: 10.3390/jcm11061588

Year: 2022

Utility of tocilizumab in autoimmune eye diseases.

DOI: 10.1080/14712598.2022.2066971

Year: 2022

Biologic therapy in refractory Neurobehçet's disease: a multicenter study of 41 patients and literature review.

DOI: 10.1093/rheumatology/keac097

Year: 2022

Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?

DOI: 10.3390/biomedicines10040851

Year: 2022

Correction: Ferraz-Amaro et al. SCORE2 Assessment in The Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics 2021, 11, 2363

DOI: 10.3390/diagnostics12020521

Year: 2022

Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.

DOI: 10.55563/clinexprheumatol/8mku9c

Year: 2022

Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes.

DOI: 10.55563/clinexprheumatol/9ipkcs

Year: 2021

Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.

DOI: 10.1016/j.autrev.2021.102830

Year: 2021

Endothelial Progenitor Cells: Relevant Players in the Vasculopathy and Lung Fibrosis Associated with the Presence of Interstitial Lung Disease in Systemic Sclerosis Patients

DOI: 10.3390/biomedicines9070847

Year: 2021

What are the Challenges in Addressing Behavioral Risks?

How Does Epidemiology Contribute to Improved Outcomes?

What Are Risk Assessment Models?

How Is the Program Evaluated?

What is a Host in Epidemiology?

What Are the Eligibility Requirements?

What is Waist to Hip Ratio?

How can the adverse health effects of radioactive waste be mitigated?

What Techniques Are Used for Data Matching?

What Are the Challenges in Studying Neurological Symptoms Epidemiologically?

Partnered Content Networks

Relevant Topics